RESUMEN
We examined a total of 194 patients over 18 years of age with chronic prostatitis syndrome and no evidence of structural or functional lower genitourinary tract abnormalities. The following data were obtained for each patient: clinical history--the severity of chronic prostatitis symptoms scored by a Croatian translation of the NiH CPSI questionnaire, clinical status including digitorectal examination, urethral swab specimens, and selective samples of urine and expressed prostatic secretion, according to the 4-glass localization test (meares and Stamey localization technique). Patients were treated orally with antimicrobial agents in doses and duration according to clinical practice in Croatia. An infectious etiology was determined in 169 (87%) patients. Chlamydia trachomatis was the causative pathogen in 38 (20%), Trichomonas vaginalis in 35 (18%), Enterococcus in 36 (19%) and Escherichia coli in 35 (18%) patients. In the remaining 25 patients the following causative pathogens were found: Ureaplasma urealyticum, Proteus mirabilis, Klebsiella pneumoniae, Streptococcus agalactiae and Pseudomonas aeruginosa. Comparison of symptoms scores and effect on quality of life has shown that the most severe clinical presentation of disease was recorded in patients with chronic bacterial prostatitis caused by E. coli and Enterococcus (p<0.001). Clinical success was paralleled by bacteriological eradication in chronic bacterial prostatitis caused by C. trachomatis, Enterococcus and E. coli (kappa >0.2<0.5), but not in inflammatory chronic pelvic pain syndrome caused by T. vaginalis.
Asunto(s)
Antiinfecciosos/uso terapéutico , Prostatitis/complicaciones , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Anciano , Enfermedad Crónica , Humanos , Masculino , Persona de Mediana Edad , National Institutes of Health (U.S.) , Calidad de Vida , Síndrome , Estados Unidos , Adulto JovenAsunto(s)
Antibacterianos/uso terapéutico , Azitromicina/uso terapéutico , Chlamydia trachomatis/patogenicidad , Infecciones por Chlamydiaceae/tratamiento farmacológico , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Adulto , Anciano , ADN Bacteriano/análisis , Diagnóstico Diferencial , Técnica del Anticuerpo Fluorescente Directa , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Prostatitis/microbiología , Urinálisis , Orina/microbiologíaAsunto(s)
Antiinfecciosos/uso terapéutico , Metronidazol/uso terapéutico , Prostatitis/microbiología , Tricomoniasis/complicaciones , Trichomonas vaginalis/patogenicidad , Animales , Antiinfecciosos/administración & dosificación , Enfermedad Crónica , Esquema de Medicación , Humanos , Inflamación , Masculino , Metronidazol/administración & dosificación , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Tricomoniasis/diagnóstico , Tricomoniasis/tratamiento farmacológicoRESUMEN
A total of 123 patients, older than 18 years of age, with symptoms of chronic prostatitis and inflammatory findings as well as the presence of Chlamydia trachomatis confirmed by DNA/RNA DIGENE hybridization method in expressed prostatic secretion or in voided bladder urine collected immediately after prostatic massage, were examined. The patients were randomized to receive a total of 4.5 g of azithromycin for 3 weeks, given as a 3-day therapy of 1 x 500 mg weekly or clarithromycin 500 mg b.i.d. for 15 days. Patients' sexual partners were treated at the same time. Clinical and bacteriological efficacy were evaluated 4-6 weeks after the end of therapy. In the group of patients with chronic chlamydial prostatitis the eradication rates (azithromycin 37/46, clarithromycin 36/45) and the clinical cure rates (azithromycin 32/46, clarithromycin 32/45) were not significantly different with regards to the administered drug (p > 0.05). In the group of patients with asymptomatic chlamydial prostatitis the eradication rates (azithromycin 11/16, clarithromycin 10/15) were not significantly different with regards to the administered drug (p = 1.00, OR = 1.1).